Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study Objective: To evaluate the effect of fingolimod 0.5 mg versus intramuscular interferon β-1a (30 μg) on ALC and its relationship with infections in paediatric-onset multiple sclerosis (POMS) up to 4 years. Methods: We[…]
Optic neuritis management in children Uni- or bilateral pediatric optic neuritis is a recurrent disease if not common. It associates a decrease in visual acuity and headaches sometimes which are not very specific in children. The diagnosis requires a precise and urgent ophthalmological investigation that will specify the visual acuity, pupillary reflex, funduscopic examination, visual[…]
POUR LES PERSONNES ATTEINTES DE SEP, NMO ET AUTRES PATHOLOGIES DEMYELINISANTES Selon les recommandations gouvernementales publiées le 1er septembre 2020 (service-public.fr), une personne est considérée comme vulnérable si elle se trouve dans l’une des situations suivantes : ETUDE COVI-SEP L’objectif principal de cette étude était de définir la présentation clinique de l’infection par la COVID-19[…]
Our Neuropediatrics Department is currently participating in the CHARGE clinical trial : An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension. The CHARGE study, set up by[…]
Our center is also participating in the PARADIGMS study : A two-year, double-blind, randomized, multicenter, activecontrolled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase. Currently, only the extension phase is open[…]
A new national diagnostic and care protocol (PNDS), dedicated to Neuromyelitis optica spectrum disorder (NMOSD), is currently under development. This project, based on current international recommendations, aims to harmonize and explain the management and the care path of patient suffering from this pathology. This PNDS will be produced in close collaboration with experts from the[…]
